SPY311.36-0.82 -0.26%
DIA263.33+0.16 0.06%
IXIC9,615.81-67.10 -0.69%
News
PEN
--
0.00%
--
Penumbra, Inc. to Present at the William Blair 40th Annual Growth Stock Conference
Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the William Blair 40th Annual Growth Stock Conference on Tuesday, June 9, 2020.
PR Newswire · 6d ago
Penumbra Reports Launch Of $100M Common Stock Offering
Benzinga · 05/27 20:09
Penumbra, Inc. Announces Launch of Offering of $100,000,000 of Shares of its Common Stock
Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All of the shares of common stock to be sold in the of
PR Newswire · 05/27 20:05
IPO Update: Inari Medical Proposes IPO Terms
Seeking Alpha - Article · 05/18 18:15
Penumbra, Inc. Announces Virtual 2020 Annual Meeting of Stockholders
PR Newswire · 05/15 21:05
Penumbra Announces Management Transition
PR Newswire · 05/12 21:05
Penumbra, Inc. (PEN) CEO Adam Elsesser on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/10 04:10
JP Morgan Maintains Overweight on Penumbra, Raises Price Target to $200
JP Morgan maintains Penumbra (NYSE:PEN) with a Overweight and raises the price target from $175 to $200.
Benzinga · 05/08 16:22
Citigroup Maintains Buy on Penumbra, Raises Price Target to $214
Citigroup analyst Joanne Wuensch maintains Penumbra (NYSE:PEN) with a Buy and raises the price target from $192 to $214.
Benzinga · 05/08 11:23
Penumbra Inc (PEN) Q1 2020 Earnings Call Transcript
Motley Fool · 05/08 08:31
Penumbra Q1 EPS $0.040 Misses $0.130 Estimate, Sales $137.300M Beat $136.280M Estimate
Penumbra (NYSE:PEN) reported quarterly earnings of $0.040 per share which missed the analyst consensus estimate of $0.130 by 69.23 percent. This is a 82.61 percent decrease over earnings of $0.230 per share from the same
Benzinga · 05/07 20:31
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.)
Benzinga · 05/07 11:42
Medical Products Stock Earnings on May 7: BDX, ABC & More
Zacks · 05/06 14:07
Vanguard Health Care Fund's Top 5 1st-Quarter Trades
GuruFocus.com · 05/01 21:55
Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for
Zacks · 04/30 17:34
Penumbra (PEN) Gains But Lags Market: What You Should Know
Zacks · 04/29 22:50
Penumbra, Inc. to Present at the Bank of America Merrill Lynch 2020 Health Care Conference
Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Bank of America Merrill Lynch 2020 Health Care Conference on Wednesday, May 13, 2020.
PR Newswire · 04/29 20:05
Penumbra, Inc. Schedules First Quarter 2020 Earnings Release and Conference Call for May 7, 2020
PR Newswire · 04/23 21:05
Bull of the Day: Penumbra (PEN)
Zacks · 04/09 10:23
Canaccord Genuity Maintains Buy on Penumbra, Lowers Price Target to $184
Canaccord Genuity maintains Penumbra (NYSE:PEN) with a Buy and lowers the price target from $186 to $184.
Benzinga · 04/07 16:06